

IOVC 2022

List of Poster Presentations

As of October 19, 2022

Poster Presentation No.	Presenting Author	Abstract Title
Category: 1. Payloads and Mechanisms of Action		
P001	Francois Marie Ngako Kadji	Stability of viruses in Hydrolyzed gelatin formulation
P002	Demi van der Horst	Nrf2-addiction creates a niche for oncovirotherapy in lung cancer by suppressing antiviral innate immunity
P003	Geertje van der Horst	Oncolytic reoviruses R124 and mutant jin-3 display anti-tumor and immune stimulatory effects in preclinical bladder cancer models
P004	Bianca Karpinecz	Novel erythrocyte-derived encapsulation platform improves oncolytic vaccinia virus infectivity and reduces immunogenicity
P005	Ikuho Ishigami	Elucidation of the Mechanism of Reovirus-mediated Antifibrotic Effects in Activated Hepatic Stellate Cells
P006	Gemma Pidelaserra-Marti	Immunological determinants of oncolytic measles virotherapy
P007	Maho Eguchi	Involvement of IPS-1-dependent signaling in reovirus-induced tumor infiltration of CD8+ cells
P008	Eftychia Stavarakaki	Towards personalized oncolytic virotherapy: differential response to four oncolytic viruses in primary glioblastoma cultures identifies virus specific susceptibility signatures
P009	Ryohei Shoji	Metabolic reprogramming by anti-mitochondrial agent promotes the antitumor efficacy of telomerase-specific oncolytic adenoviruses against virotherapy-resistant pancreatic cancer
P010	Shinsuke Nakao	Oncolytic vaccinia virus armed with IL-7 and IL-12 alters intratumoral immune status, sensitizing tumors to immune checkpoint blockade
P011	Huy-Dung Hoang	Adaptation of mRNA translation boosts transgene expression and the anticancer efficacy of oncolytic HSV1
P013	Jahanara Rajwani	Oncolytic rhabdovirus infection of non cancer cells improves antitumor immunity by increasing tumor antigen presentation
P014	Michela Muscolini	Identification of host resistance genes contributing to oncolytic virus resistance in pancreatic ductal adenocarcinoma
P015	Bangxing Hong	oHSV-P10 counters gliomas cell-mediated barrier to radiotherapy
P016	Victoria Jennings	Oncolytic Rhabdoviruses expressing miRNA enhance anti-tumour immunity
P017	Reza Rezaei	development of novel drug inducible synthetic promoters to improve the safety and efficacy of oncolytic vaccinia virus
P018	Kseniya Setgeevna	Pre-clinical evaluation of the intravenous administrated oncolytic Newcastle disease virus for therapeutic use against colorectal cancer and glioma
P019	Svetlana Atasheva	Oncolytic adenovirus therapy transforms immune landscapes of lung cancer tumors in mice and in human surgical explants.
P020	Sara A Collins	RRV-Mediated Prodrug Activator Gene Therapy for Metastatic Ovarian Cancer: Assessment in Experimental Models of Peritoneal Carcinomatosis
P021	Sara A Collins	A Binary Retroviral Replicating Vector Platform for Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 Delivery

Poster Presentation No.	Presenting Author	Abstract Title
P022	Michael Bergmann	TNF induction is essential for oncolytic influenza A virus induced cancer regression and tumor associated macrophage repolarization
P023	Michael Bergmann	Complex primary CRC organoid cultures to compare immunogenic effects of oncolytic influenza A viruses and standard chemotherapy on macrophages
P024	Tatiana Kudling	Intratumoral expression of interleukin 7 with an oncolytic adenovirus improves anti-tumor response and activation of tumor-infiltrating lymphocytes in vivo and ex vivo
P025	Marion Grard	Characterization of tumor resistance factors to oncolytic measles virus in 3D model
P026	Morgane Fouet	Tumor cells infected by an oncolytic virus activate human gamma-delta T cells.
P027	Santeri Artturi Pakola	Treatment of pancreatic ductal adenocarcinoma using an oncolytic adenovirus coding for a modified version of the interleukin 2 molecule with ablated binding to T regulatory cells
P028	Shumpei Uchida	Oncolytic Virus Therapy with HSV-1 for Hematological Malignancies
P029	Yen-Ju Chen	A novel oncolytic virus enhances anti-cancer immunity in a huMice model
P030	Camille Chatelain	Variable effect of healthy cells on measles virus oncolytic activity in thoracic cancers
P031	Shinichi Esaki	Intravenous injection of oncolytic virus G47delta for murine metastatic lung tumors
P032	Yuta Takeshima	NOVEL ONCOLYTIC HSV-1 WITH TISSUE-SPECIFIC ICP6 GENE REGULATION EXHIBITS ENHANCED EFFICACY IN PROSTATE CANCER
P033	Megan Montoya	Retroviral replicating vector-mediated transcriptional reprogramming of immature myeloid cells in the glioma microenvironment
P034	Maria Barcova	Universal mesenchymal stem-cell-based delivery of tumor-selective retroviral replicating vectors
P035	Kazuho Inoko	Interferon-expressing oncolytic adenovirus induces antitumor immunity in hamster pancreatic cancer models
P036	Tomoko Fujiyuki	Anti-tumor activity of a recombinant measles virus against canine primary lung adenocarcinoma cells
P037	Philippe Erbs	Oncolytic virus therapy using genetically engineered vaccinia virus TG6002 in dogs diagnosed with malignant solid tumors
P038	Kanako Moritoh	Anti-tumor immunity elicited by a recombinant measles virus (rMV-SLAMblind) cancer therapy
Category: 2. Combination Therapies		
P039	Shuhei Shinoda	Interferon-expressing oncolytic adenovirus with chemoradiation suppressed tumor growth with higher number of tumor-infiltrating lymphocytes
P040	David Olnagier	Itaconate and derivatives potentiate oncolytic virotherapy by suppressing antiviral innate immunity
P041	Abigail Louise Connor	Utilising oncolytic reovirus to enhance immune cell activation in hepatocellular carcinoma and understand the relevance of tumour mutation burden.
P042	Boaz Wong	Pevedonistat, a first in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVd51 oncolytic virotherapy
P043	Zaid Taha	Syngeneic mouse model of human HER2+ breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus

Poster Presentation No.	Presenting Author	Abstract Title
P044	Nouf Alluqmani	Vanadate-enhanced oncolytic virus immunotherapy mediates the anti-tumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines
P045	Brett Lee Roach	Exploring novel viro-immunotherapies using "armed" oncolytic adenoviruses and adoptive T-cell therapy to target pancreatic ductal adenocarcinoma
P046	Katharina Susek	Involvement of surface receptors in NK cell mediated recognition of HSV-OV infected cancer target cells
P047	Nadine van Montfoort	Pelareorep synergizes with CD3-bispecific antibody therapy in cold tumors
P048	Masatoshi Tagawa	A drug targeting the G2/M phases enhances replications and cytotoxicity of oncolytic adenoviruses in p53-deficient cells.
P049	Mona Aboalea	Title Armed Oncolytic Virus Expressing CAR Targets in Solid Tumors Synergizes CAR-T Cell Therapy
P050	Praveen Bommareddy	Clinical biomarker studies of RP2 monotherapy and combined with nivolumab in patients with advanced solid tumors
P051	Motomu Nakatake	HDAC inhibitor treatment improves therapeutic efficacy of fusogenic oncolytic vaccinia virus through enhancing the cell-cell fusion
P052	Victoria Gilchrist	Novel pharmacoviral combinations that potentiate oncolytic herpes simplex virus 1 infection in glioblastoma cell models
P053	Mathieu JF Crupi	Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer
P054	Ningbo Zheng	Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance
P056	Yoshihiro Otani	Modulation of oHSV-induced NOTCH signaling enhances anti-tumor immunity in brain tumors
P057	Juan Fueyo	Combination of oncolytic adenovirus therapy with adaptive cell therapy enhances systemic anti-tumor immunity
P058	Florian Gerhard Klein	Targeting BRD4 potentiates the oncolytic activity of XVir-N-31 by mimicking E1A13S functionality
P059	Saida Dadi-Mehmetaj	Voyager V1 (VV1) oncolytic virus combined with immune checkpoint therapy boosts CTL responses to multiple tumor antigens and correspondingly deepens tumor responses in murine models of melanoma, lung and colon cancer.
P060	Ahmed Majeed Al-Shammari	Oncolytic Newcastle Disease virus combined with methylene blue photodynamic therapy and reduces breast cancer growth in a mouse model
P061	Hiroshi Nakashima	Tasquinimod enhances anti-tumor effect of oncolytic HSV-1 in glioblastoma by inhibiting recruitment of MDSCs and angiogenesis
P062	Erika Vojtasova	Ultrasound-enhanced delivery and improved efficacy of an oncolytic vaccinia virus in a murine bladder cancer model
P064	Akram Alwithenani	DMF Improves Oncolytic HSV-1 In Cancer
P065	Maria Davola	Immunogenic cell death is necessary but not sufficient for oBHV-1 mediated therapeutic efficacy
P066	Hyo Min An	Combination of cytokine-expressing oncolytic adenoviruses and immune checkpoint inhibitor overcomes immunosuppressive tumor microenvironment by remodeling physical and immunological aspects of a poorly immunogenic tumor
P067	Hiroki Niwa	Combination therapy of retroviral replicating-vector mediated gene therapy and anti PD-1 antibody shows favorable therapeutic effects for an immunocompetent murine pancreatic cancer model
P068	Marie G. Szczeponik	PharmacoViroTherapy: Boosting oncolytic viruses by small molecule compounds

Poster Presentation No.	Presenting Author	Abstract Title
P069	Karen Janet Scott	Single Versus Multiple Intravenous Oncolytic Virus Infusions: Implications for Rationalised Scheduling of Therapy in Hepatocellular Carcinoma.
P070	Jia Yao	Combination therapy with novel oncolytic adenovirus improves therapeutic efficacy of disseminated lung cancer
P071	Joanna Jazowiecka-Rakus	Human adipose tissue-derived mesenchymal stem cells as a carrier of oncolytic myxoma knock-out construct for the therapy of experimental murine glioma
Category: 3. Novel Viral Platforms		
P072	Ryosuke Ono	Oncolytic adenovirus serotype-35 suppresses tumor growth via activation of natural killer cells
P073	Natalie Winder	Macrophage delivered HSV1716 is active against Triple Negative Breast Cancer
P074	Faith Howard	Bugs as drugs - bacterial derived nanomagnets enhance tumour targeting and oncolytic activity of HSV-1 virus
P075	Munitta Muthana	Breast cancer extracellular vesicles transfer viral cargo following infection with oncolytic virotherapy
P076	Mizuho Sato-Dahlman	Engineering the cancer-targeted oncolytic adenovirus with fiber modification for systemic administration.
P077	Heechung Kwon	Novel oncolytic herpes simplex virus type 1 (oHSV-1) platform for onco-immunotherapy: systemic delivery and efficacy of GCM-101 with host immune evasion
P078	Fuminori Sakurai	Reovirus-infected cell-derived small extracellular vesicles efficiently suppress the subcutaneous tumor growth following intravenous administration in mice
P079	Sara Cuadrado-Castano	Avia Paramyxovirus 4 (APMV-4) Oncolytic Virotherapy leads to complete responses and long-term anti-tumor memory in preclinical melanoma, colon carcinoma and lymphoma tumor models
P080	Edward Wenge Wang	Conditional activation of oncolytic and immune responses against ovarian cancer
P081	Yuya Nishikawaji	An optimal promoter driving cytokine transgene for safe and efficient oncolytic virus immunotherapy
P082	Ema Mitsui	Oncolytic adenovirus-mediated p53 gene therapy targets the tumor-microenvironment to improve anti-tumor efficacy for peritoneal metastasis of gastric cancer.
P083	Motomu Nakatake	Fusogenic oncolytic vaccinia virus increases immune checkpoint blockade sensitivity by remodeling the tumor immune microenvironment
P084	Shohei Miyamoto	Preclinical studies of a second-generation miRNA-targeted oncolytic coxsackievirus B3
P085	Susumu Uchiyama	Biophysical characterizations and quality assessment of AAV vectors for gene therapy
P086	Toshihiro Uchihashi	Safety and efficacy of postoperative G47 Δ ; in mouse tongue cancer models
P087	So Young Yoo	Pan-cancer-specific engineered oncolytic vaccinia virus
P088	Koji Araki	Oncolytic Sendai virus as a novel treatment option for head and neck squamous cell carcinoma
P089	Margaret Duffy	THEO-260 - a novel oncolytic virotherapy for stromal rich tumours
P090	Sarah Danklmaier	Prediction and validation of MHC class I presented T cell epitopes of the oncolytic virus VSV-GP in BALB/c mice

Poster Presentation No.	Presenting Author	Abstract Title
P091	Xiao Xiang	Unlocking the potential of Reovirus to combat emerging and recurrent cancers
P092	Susan Clark	Oncolytic Measles Virotherapy in Synovial Sarcoma
P093	Le Thai Minh Duy	Development of Tumor Microenvironment Responsive Hydrogel for Sustained Release of Nanomaterial-modified Oncolytic Adenovirus Complex for Cancer Treatment
P094	Kasala Dayananda	Shielding of oncolytic adenovirus surface with cationic polymer attenuates the induction of antiviral immune response while enhancing antitumor immune response to effectively prevent metastasis
P095	Joseph C. Glorioso	Targeted delivery of EGFR-retargeted oncolytic herpes simplex viruses in a xenograft model of glioblastoma.
P096	Masaki Nagasato	A Tumor-Targeting Adenovirus with High Gene Transduction Efficiency for Primary Pancreatic Cancer and Ascites Cells
P097	Akira Sakamoto	Coxsackievirus A11 is an Immunostimulatory Oncolytic Virus that Induces Complete Tumor Regression in a Human Non-Small Cell Lung Cancer Xenograft Model
P098	Shuji Kubo	Retroviral replicating vector-mediated prodrug-activator gene therapy for gastric cancer
P099	Emiko Sonoda	Prodrug-activator gene therapy for canine cancers with retroviral replicating vectors
P100	Akihito Inagaki	Development of GALV-based retroviral replicating vectors for prodrug activator gene therapy in preclinical glioma models.
P101	Lorenz Hanesch	Dendritic cell activation by rVSV-NDV-mediated oncolysis and its application as a novel dendritic cell vaccine approach
P102	Misako Yoneda	Histopathological analysis of nectin-4 expression in breast cancer
P103	Hayato Akimoto	Examination of oncolytic measles virus therapy for pancreatic cancer.
Category: 4. Clinical Trials		
P104	Saurabh Gautam	Single-step rapid chromatographic purification process for clinical stage oncolytic VSV-GP
P105	Emma West	Intravenous Pexa-Vec Infusion Results in a Differential Immune Response between Cancer Patients
P106	Toshihiko Okazaki	Key consideration for GMP compliant process development of manufacturing of Coxsackie virus type B3
P107	Takahiro Maruno	Comprehensive particle characterization of adeno-associated virus vector by multiwavelength sedimentation velocity analytical ultracentrifugation

*P012, P055 and P063 have been withdrawn.